Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Moving to component management & traceability: progress, barriers, and the way forward

Almirall joins IL-2 push in autoimmunity with $507m Simcere deal

Name change for Johnson & Johnson offshoot to Kenvue

Getting approval will only be the first challenge facing lecanemab

FDA clears Dupixent as first drug for rare skin disorder

botulinum neurotoxins

John-Chaddock

Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems

George Underwood BoNTs, Botox, botulinum neurotoxins, focal spasticity, Ipsen, neurology, neurotoxins, stroke 0 Comment

Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get

X

Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems

https://pharmaphorum.com/r-d/views-analysis-r-d/ipsens-john-chaddock-on-making-neurotoxins-a-priority-for-healthcare-systems/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

FDA drops PreCert report, new digital health guidances
Whistleblower gets $250m as Biogen settles US kickbacks case
Biogen, Eisai say lecanemab has aced phase 3 Alzheimer's study
NICE backs 'real-world' wearable devices for Parkinson's disease
Lava fires up a $700m cancer licensing deal with Seagen

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com